Incyte (INCY) Interest Coverage Ratio Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.97% |
| Dec 31, 2025 | 8.50% |
| Sep 30, 2025 | 138.10% |
| Jun 30, 2025 | 18.34% |
| Mar 31, 2025 | 17.94% |
| Dec 31, 2024 | 35.68% |
| Sep 30, 2024 | -3.45% |
| Jun 30, 2024 | -34.07% |
| Mar 31, 2024 | -0.68% |
| Dec 31, 2023 | 41.09% |
| Sep 30, 2023 | 35.01% |
| Jun 30, 2023 | 7.18% |
| Mar 31, 2023 | 18.16% |
| Dec 31, 2022 | 88.05% |
| Sep 30, 2022 | 24.00% |
| Jun 30, 2022 | 81.79% |
| Mar 31, 2022 | 57.33% |
| Dec 31, 2021 | 87.78% |
| Sep 30, 2021 | 196.21% |
| Jun 30, 2021 | 143.30% |
| Mar 31, 2021 | 138.63% |
| Dec 31, 2020 | 196.60% |
| Sep 30, 2020 | 304.92% |
| Jun 30, 2020 | 259.43% |
| Mar 31, 2020 | -358.12% |
| Dec 31, 2019 | 139.29% |
| Sep 30, 2019 | 105.75% |
| Jun 30, 2019 | 167.87% |
| Mar 31, 2019 | 157.09% |
| Dec 31, 2018 | -81.97% |
| Sep 30, 2018 | 115.87% |
| Jun 30, 2018 | 162.36% |
| Mar 31, 2018 | -246.43% |
| Dec 31, 2017 | 30.95% |
| Sep 30, 2017 | 143.75% |
| Jun 30, 2017 | 70.00% |
| Mar 31, 2017 | -49.26% |
| Dec 31, 2016 | -11.75% |
| Sep 30, 2016 | 21.20% |
| Jun 30, 2016 | 26.37% |
| Mar 31, 2016 | 34.60% |
| Dec 31, 2015 | 0.76% |
| Sep 30, 2015 | 66.38% |
| Jun 30, 2015 | -20.02% |
| Mar 31, 2015 | 20.15% |